Single nucleotide polymorphism rs4961 in the adducin 1 gene is not associated with gastric cancer or preneoplastic cancer lesions

• Published in: Oncology letters Vol. 28; no. 4; p. 455
• Main Authors: Oca, Ernesto Prado-Montes De, Perea-Diaz, Francisco Javier, Magana-Torres, Maria Teresa, Agreda-Fernandez, Mireya Yamel, Ruiz-Pinon, Karime, Sanchez-Lopez, Josefina Yoaly, Torre-Guzman, Samantha Rebeca De La
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.10.2024; Spandidos Publications UK Ltd
• Subjects: Breast cancer; Cytoskeletal proteins; Datasets; Endoscopy; Gastric cancer; Genes; Genetic aspects; Genetic testing; Health aspects; Hypertension; Males; Mutation; Polymorphism; Precancerous conditions; Proteins; Risk factors; Salt; Signal transduction; Single nucleotide polymorphisms; Software; Stomach cancer; White people; Mexico; adducin protein; oncogenic signal transduction; renal cell cancer; gastric cancer; breast cancer susceptibility; salt-sensitive hypertension
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2024.14588

Gastric cancer (GC) is the fourth most deadly cancer globally. The adducin 1 (ADD1) protein is involved in oncogenic signal transduction pathways in several types of cancer, and the rs4961 variant (c.1378 G>T, p.Gly460Trp) of the gene is associated with salt-sensitive hypertension, renal cell cancer and breast cancer susceptibility; however, it has not been investigated in GC. The aim of the present study was to evaluate the association between the rs4961 variant and the development of GC and preneoplastic gastric lesions (PGLs) in a population from western Mexico. A total of 225 individuals who underwent an endoscopy were evaluated, of which 71 patients had histopathologically diagnosed GC and 53 patients had PGLs, with 101 patients used as controls. The rs4961 variant was genotyped by using PCR and DNA sequencing. The frequency of the mutated homozygous genotype (TT) of the rs4961 variant was <10% in the three evaluated groups, and the frequency of the minor allele (T) was <21% in the GC, PGL and control groups. Genotypic and allelic frequencies were similarly distributed in all of the studied groups (P>0.05). In summary, in the study population, the rs4961 variant was not associated with GC risk; however, its role in other populations and in other types of cancer is worthy of future research.